Regulus Therapeutics (RGLS) Announces Quarterly Earnings Results

Regulus Therapeutics (NASDAQ:RGLS) released its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03, Yahoo Finance reports. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 99,868.07% and a negative return on equity of 201.84%.

Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down $0.05 on Wednesday, hitting $0.83. 1,886,317 shares of the company were exchanged, compared to its average volume of 680,160. Regulus Therapeutics has a 12-month low of $0.79 and a 12-month high of $1.95. The stock has a market capitalization of $91.51, a price-to-earnings ratio of -1.10 and a beta of 1.71.

A number of research firms have weighed in on RGLS. Chardan Capital restated a “neutral” rating on shares of Regulus Therapeutics in a research report on Tuesday, January 16th. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Wednesday, January 24th. Leerink Swann started coverage on shares of Regulus Therapeutics in a research report on Friday, January 5th. They issued an “outperform” rating and a $2.00 target price for the company. BMO Capital Markets set a $1.00 target price on shares of Regulus Therapeutics and gave the company a “hold” rating in a research report on Thursday, March 8th. Finally, Wedbush reiterated an “outperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $2.20.

TRADEMARK VIOLATION NOTICE: “Regulus Therapeutics (RGLS) Announces Quarterly Earnings Results” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Earnings History for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply